Latest Convertible Notes News

Page 4 of 91
Tartana Minerals has accelerated exploration after a shareholder-driven leadership overhaul, but its cash runway is shorter than the time to its next major debt maturity. Assays from Nightflower, copper drilling and regional sampling now carry added significance as the company negotiates refinancing and reviews its stalled copper sulphate operation.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.
Victor Sage
Victor Sage
30 Oct 2026
Micro-X has reported a sharp improvement in Rover order activity and more than $3 million in annualised cost savings, while redirecting its strategy towards medical CT. The September quarter still consumed $4.4 million in operating cash, leaving funding dependent on further note proceeds, an expected tax refund and milestone receipts.
Victor Sage
Victor Sage
30 Oct 2026
Identitii lifted annual recurring revenue 21% to $865,000 and expanded its sales pipeline 70% during the September quarter as new transaction-monitoring tools went live. But the fintech ended the period with negative cash of $44,000, leaving its near-term funding position dependent on further convertible-note proceeds and improved operating cash flow.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Dome Gold Mines has reached a regulatory milestone at its Sigatoka heavy mineral sands project, but remains suspended from trading with no cash on hand and its annual audit unfinished. The company is seeking up to A$3 million through convertible notes while it negotiates funding for valuation work and working capital.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Cyprium Metals has secured an approximately A$20.7 million institutional placement and outlined a proposed debt extension that could take its staged Nifty funding package to A$83 million. The capital is aimed at advancing the open-pit feasibility study, infrastructure upgrades and a major SXEW expansion while first cathode production remains targeted for Q4 2026.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Carbonxt is forecasting at least A$22 million of FY27 revenue after securing larger customer orders, but the growth plan remains tied to a delayed Kentucky facility and shareholder approval of a proposed balance sheet restructure. Cash stood at just A$0.7 million after a A$1.0 million operating outflow in the September quarter.
Victor Sage
Victor Sage
30 Oct 2026
Dotz Nano has secured commitments for a A$2 million placement while proposing to acquire PRF Technologies’ GridFeed software for US$1 million paid over 21 months. The move would broaden its energy strategy from building-level cooling optimisation into renewable generation, storage and grid analytics, but the deal and much of the commercial pipeline remain conditional.
Victor Sage
Victor Sage
30 Oct 2026
Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
Ada Torres
30 Oct 2026

Browse the archive

Full archive